European prize for mobile vaccination units The Netherlands’ mobile vaccination units (prikbussen) have been selected as a best-practice method for the European project ‘Overcoming Obstacles to Vaccination’.
Concerns over falling vaccination coverage within National Immunisation Programme The percentage of children vaccinated within the National Immunisation Programme (NIP) has fallen for the second year in a row, according to the 2022 report ‘Vaccination Coverage and Annual Report of the Dutch National Immunisation Programme'. RIVM is concerned about this decline.
Number of participants in Combined Lifestyle Intervention tops 73,000 By the end of 2022, the number of participants in the Combined Lifestyle Intervention (CLI) had grown to over 73,000. This is according to a semi-annual report by RIVM. The figure represents a 51% increase since the end of May 2022. The number of participants was around 48,000 at that time.
Safe recycling of textiles possible, but still in its infancy Textiles are produced using chemicals. Although many hazardous chemicals may no longer be used in textile production, they may still be present in donations of old clothing. RIVM has conducted a study into the safety of recycled textiles.
Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
Less greenhouse gas emissions across the supply chain: survey for policy development The Dutch Climate Agreement contains measures to reduce greenhouse gas emissions in the Netherlands. Many products used in the Netherlands are manufactured abroad.
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.